1.Late but effective long-term response to splenectomy in the treatment of immune thrombocytopenia.
Laura SCARAMUCCI ; Marco GIOVANNINI ; Andrea TENDAS ; Pasquale NISCOLA ; Paolo DE FABRITIIS
Blood Research 2013;48(4):297-298
No abstract available.
Splenectomy*
;
Thrombocytopenia*
2.Primary mixed-type autoimmune hemolytic anemia concomitant with acute splanchnic venous thrombosis of idiopathic origin in a young woman: an unexplained association.
Laura SCARAMUCCI ; Marco GIOVANNINI ; Pasquale NISCOLA ; Alessio PERROTTI ; Paolo DE FABRITIIS
Blood Research 2013;48(4):292-293
No abstract available.
Anemia, Hemolytic, Autoimmune*
;
Female
;
Humans
;
Venous Thrombosis*
3.Successful re-treatment with azacitidine in a patient with low blast count AML transformed from MDS after suspension of this agent.
Pasquale NISCOLA ; Andrea TENDAS ; Laura SCARAMUCCI ; Marco GIOVANNINI ; Stefano FRATONI ; Paolo DE FABRITIIS
Blood Research 2015;50(2):113-114
No abstract available.
Azacitidine*
;
Humans
4.Evolution of chronic myelomonocytic leukemia from refractory anemia: the unusual course of a myelodysplastic syndrome.
Pasquale NISCOLA ; Andrea TENDAS ; Laura SCARAMUCCI ; Marco GIOVANNINI ; Stefano FRATONI ; Paolo DE FABRITIIS
Blood Research 2013;48(2):152-153
No abstract available.
Leukemia, Myelomonocytic, Chronic
;
Myelodysplastic Syndromes
5.Long-term hematological response in a patient with 5q- syndrome after suspension of lenalidomide therapy and further improvement with deferasirox therapy.
Pasquale NISCOLA ; Andrea TENDAS ; Laura SCARAMUCCI ; Roberta MEROLA ; Gianfranco CATALANO ; Paolo DE FABRITIIS
Blood Research 2014;49(2):130-137
No abstract available.
Humans
6.Primary acquired chronic pure red cell aplasia refractory to standard treatments: remission with rituximab.
Andrea TENDAS ; Pasquale NISCOLA ; Laura SCARAMUCCI ; Luca CUPELLI ; Alessio Pio PERROTTI ; Paolo DE FABRITIIS
Blood Research 2016;51(2):137-138
No abstract available.
Red-Cell Aplasia, Pure*
;
Rituximab*
7.Steroid-refractory immune thrombocytopenia in the era of the new thrombomimetic drugs: is there still a role for rituximab?.
Massimiliano PALOMBI ; Laura SCARAMUCCI ; Marco GIOVANNINI ; Malgorzata Monika TRAWINSKA ; Pasquale NISCOLA ; Paolo DE FABRITIIS
Blood Research 2016;51(1):66-66
No abstract available.
Thrombocytopenia*
;
Rituximab
8.Concomitant transformation of monoclonal gammopathy of undetermined significance to multiple myeloma and of essential thrombocythemia to acute biphenotypic leukemia 37 years after initial diagnosis.
Pasquale NISCOLA ; Gianfranco CATALANO ; Stefano FRATONI ; Laura SCARAMUCCI ; Paolo DE FABRITIIS ; Tommaso CARAVITA
Blood Research 2013;48(3):228-230
No abstract available.
Leukemia, Biphenotypic, Acute
;
Monoclonal Gammopathy of Undetermined Significance
;
Multiple Myeloma
;
Paraproteinemias
;
Thrombocythemia, Essential
9.Acute myeloid leukemia arising from chronic myelomonocytic leukemia during hypomethylating therapy.
Pasquale NISCOLA ; Andrea TENDAS ; Laura SCARAMUCCI ; Marco GIOVANNINI ; Daniela PICCIONI ; Paolo DE FABRITIIS
Blood Research 2014;49(1):65-66
No abstract available.
Leukemia, Myeloid, Acute*
;
Leukemia, Myelomonocytic, Chronic*
10.Regaining the response to erythropoietin following azacitidine in chronic myelomonocytic leukemia previously evolved from refractory anemia.
Pasquale NISCOLA ; Andrea TENDAS ; Roberta MEROLA ; Giulia ORLANDI ; Laura SCARAMUCCI ; Paolo DE FABRITIIS
Blood Research 2015;50(3):181-182
No abstract available.
Anemia, Refractory*
;
Azacitidine*
;
Erythropoietin*
;
Leukemia, Myelomonocytic, Chronic*
Result Analysis
Print
Save
E-mail